Study of Magrolimab Combinations in Participants With Myeloid Malignancies

Trial ID or NCT#

NCT04778410

Status

not recruiting iconNOT RECRUITING

Purpose

The goal of this clinical study is to learn more about the safety and dosing of the study drug, magrolimab (Mag), in combination with anti-leukemia therapies in participants with acute myeloid leukemia (AML).

Official Title

A Phase 2 Multi-Arm Study of Magrolimab Combinations in Patients With Myeloid Malignancies

Eligibility Criteria

Sexes Eligible for Study: ALL
Accepts Healthy Volunteers: No
Show Less

Investigator(s)

Gabriel Mannis
Gabriel Mannis
Hematologist-Oncologist
Associate Professor of Medicine (Hematology)

Contact us to find out if this trial is right for you.

Contact

Gabriel Mannis
gmannis@stanford.edu

View on ClinicalTrials.gov